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BACKGROUND
Germline loss-of-function mutations in PALB2 are known to confer a predisposi-
tion to breast cancer. However, the lifetime risk of breast cancer that is conferred 
by such mutations remains unknown.
METHODS
We analyzed the risk of breast cancer among 362 members of 154 families who 
had deleterious truncating, splice, or deletion mutations in PALB2. The age-specific 
breast-cancer risk for mutation carriers was estimated with the use of a modified 
segregation-analysis approach that allowed for the effects of PALB2 genotype and 
residual familial aggregation.
RESULTS
The risk of breast cancer for female PALB2 mutation carriers, as compared with the 
general population, was eight to nine times as high among those younger than 40 
years of age, six to eight times as high among those 40 to 60 years of age, and five 
times as high among those older than 60 years of age. The estimated cumulative 
risk of breast cancer among female mutation carriers was 14% (95% confidence 
interval [CI], 9 to 20) by 50 years of age and 35% (95% CI, 26 to 46) by 70 years of 
age. Breast-cancer risk was also significantly influenced by birth cohort (P < 0.001) 
and by other familial factors (P = 0.04). The absolute breast-cancer risk for PALB2 
female mutation carriers by 70 years of age ranged from 33% (95% CI, 25 to 44) 
for those with no family history of breast cancer to 58% (95% CI, 50 to 66) for 
those with two or more first-degree relatives with breast cancer at 50 years of age.
CONCLUSIONS
Loss-of-function mutations in PALB2 are an important cause of hereditary breast 
cancer, with respect both to the frequency of cancer-predisposing mutations and 
to the risk associated with them. Our data suggest the breast-cancer risk for PALB2 
mutation carriers may overlap with that for BRCA2 mutation carriers. (Funded by 
the European Research Council and others.)
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PALB2 (partner and localizer of BRCA2) was originally identified as a BRCA2-inter-acting protein that is crucial for key BRCA2 
genome caretaker functions1,2; it was subsequent-
ly also shown to interact with BRCA1.3 Biallelic 
germline loss-of-function mutations in PALB2 
(also known as FANCN) cause Fanconi’s anemia, 
whereas monoallelic loss-of-function mutations 
are associated with an increased risk of breast 
cancer and pancreatic cancer.4 Previous studies 
of familial breast cancer have yielded estimates 
of risk in association with loss-of-function mu-
tations in PALB2 that are two to four times as 
high as the risk among non–mutation carriers.5-7 
In Finland, the PALB2 c.1592delT founder muta-
tion was identified in approximately 1% of 
women with breast cancer who were not selected 
on the basis of a positive family history6 and was 
associated with a risk of breast cancer that was 
increased by a factor of six, which is similar to 
the risk among carriers of deleterious BRCA2 
variants in the same country.8 In Canada, the 
PALB2 c.2323C→T (p.Glu775X) founder mutation 
was detected in approximately 0.5% of French-
Canadian women with early-onset breast cancer 
who were not selected on the basis of a positive 
family history.9 PALB2 loss-of-function mutations 
have now been observed in persons from many 
countries and are found in 0.6 to 3.9% of fami-
lies with a history of breast cancer, depending 
on the population.
Clinical testing for genes that confer a predis-
position to breast cancer has been revolution-
ized by next-generation sequencing. Multigene 
panels that allow relatively inexpensive and rapid 
genetic profiling are now in widespread use. 
However, the usefulness of this technology for 
medical follow-up is limited by incomplete in-
formation on breast-cancer risk, even for well-
documented genes. To obtain more precise and 
robust estimates of the cancer risk associated 
with loss-of-function mutations in PALB2, we 
collected data on mutation carriers and their 
relatives from multiple centers worldwide. The 
goal of our study was to estimate the risk of 
breast cancer associated with inherited loss-of-
function mutations in PALB2 on the basis of 
family data for mutation carriers from many 
locales, across multiple generations, and with 
differing family histories of cancer.
Me thods
Families
Families were identified through 14 participating 
research centers. Families were eligible for inclu-
sion if at least one family member with breast 
cancer who tested negative for BRCA1 and BRCA2 
mutations had a loss-of-function mutation in 
PALB2. Some families were ascertained through 
clinics for patients at high risk for breast cancer, 
and others were ascertained through screening 
of patients with breast cancer who were not se-
lected on the basis of a positive family history. 
In instances in which PALB2 testing was performed 
on a research basis, this was done with local 
institutional-review-board approval; family data 
were made anonymous before analysis for this 
project. Informed consent was obtained from par-
ticipants in accordance with institutional-review-
board policies and local practices at each par-
ticipating center. Families with PALB2 missense 
variants or with variants of uncertain pathogenic-
ity were excluded from the study. The lists of 
participating centers and ascertainment criteria 
are provided in Table S1 in the Supplementary 
Appendix, available with the full text of this ar-
ticle at NEJM.org.
Statistical Analysis
The inheritance patterns of disease and genotypes 
in families were used to estimate the cancer risk 
conferred by PALB2 loss-of-function mutations, 
with the use of modified complex-segregation-
analysis methods.10,11 Pedigree likelihoods were 
constructed with the use of the pedigree-analysis 
software Mendel, version 3.3,12 and a maximum-
likelihood approach was used to obtain param-
eter estimates.
For the main analysis, the phenotype of each 
female family member was defined by her age at 
breast-cancer diagnosis or, if she was unaffected, 
her age at last follow-up. Women were followed 
from 20 years of age until the age at diagnosis of 
breast, ovarian, or other cancer, age at death, age 
at last follow-up, or 80 years of age, whichever 
occurred first. For the analysis of breast-cancer 
risk, only women with a diagnosis of breast can-
cer (before a diagnosis of any other cancer) were 
assumed to be affected (see the Methods section 
in the Supplementary Appendix).
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We used two main models of genetic suscep-
tibility: a single-gene model in which all familial 
aggregation of breast cancer was assumed to be 
due to the PALB2 loss-of-function mutations and 
a model in which genetic susceptibility to breast 
cancer was due to PALB2 loss-of-function muta-
tions and to a residual component representing 
other familial effects. Under each model, the in-
cidence of breast cancer for person i was depen-
dent on the underlying PALB2 genotype and 
polygenotype (i.e., the genotype under the poly-
genic model) through a model of the form 
λi(t) = λ0(t) exp [β(t)gi + Pi], where gi = 0 for persons 
without a PALB2 mutation; gi = 1 for carriers of a 
deleterious PALB2 variant; Pi is the residual fa-
milial component, assumed to be normally dis-
tributed with mean 0 and variance σR
2; and β(t) 
is the age-specific log relative risk for carriers of 
a deleterious PALB2 variant relative to the base-
line breast-cancer incidence, λ0(t) (see the Meth-
ods section in the Supplementary Appendix). For 
all models allowing for a residual familial com-
ponent, we constrained the sum of the variance 
in breast-cancer risk due to PALB2 mutations and 
the residual variance, σR
2, to agree with external 
estimates of the total familial breast-cancer vari-
ance, σP
2, following the procedure described in 
detail elsewhere.11 The total familial variance, σP
2, 
was assumed to be equal to 1.66, a value estimated 
in previous breast-cancer segregation analyses.13,14
Because families were ascertained in multiple 
ways, failure to adjust for the methods of ascer-
tainment could have led to a biased estimation of 
cancer risk. To adjust for ascertainment, we used 
an ascertainment assumption–free approach15-17 
in which we evaluated each family separately. 
This involved dividing the data for each family 
into two components, one containing all the data 
potentially relevant to the ascertainment (F1), 
and the other containing all the data not relevant 
to the ascertainment (F2). For each family, we 
modeled the conditional likelihood, L, as being 
equal to P(F1, F2)/P(F1), where P(F1, F2) is the 
probability of observing all data in the pedigree, 
and P(F1) is the probability of observing only data 
relevant to ascertainment in the pedigree (Table 
S2 in the Supplementary Appendix).
Specifically, for families identified through 
screening for PALB2 mutations in population-
based series of breast-cancer cases, we modeled 
the conditional likelihood of observing the phe-
notypes and genotypes in the families, given the 
PALB2 mutation status, disease status, and age at 
diagnosis only of the index patient. For families 
identified through multiple affected members, 
we maximized the likelihood of observing the 
phenotypes and genotypes in the family, given 
all the disease phenotypes and the mutation 
status of the index family member. Family data 
contributed information to the analysis only if 
PALB2 was genotyped in at least one family 
member in addition to the index patient. With 
this approach to adjustment for the method of 
ascertainment, 21 families that were ascertained 
through multiple affected members and in 
which no additional family members had been 
genotyped were excluded from the analysis. At 
some study centers, recruitment of families with 
multiple affected members was based on narrower 
criteria — for example, phenotypes of first-degree 
relatives or of first-degree and second-degree rela-
tives only (Table S1 in the Supplementary Appen-
dix). For these families, ascertainment adjustment 
was based on maximizing the likelihood of ob-
serving the phenotypes and genotypes in the 
family, given the disease phenotypes of relatives 
included in the ascertainment and the mutation 
status of the index family member.
Model parameters were expressed as the natu-
ral logarithm of the ratio of cancer incidence in 
PALB2 mutation carriers relative to baseline can-
cer incidence. Parameters were estimated with 
the use of the maximum-likelihood method, and 
variances were obtained from the observed in-
formation matrix. All statistical tests were two-
sided. A P value of 0.05 or less was considered to 
indicate statistical significance.
R esult s
Families
Information was available from 175 families 
with at least one member who had breast cancer 
and a germline loss-of-function mutation in PALB2. 
After adjustment for ascertainment, 154 families 
were eligible for analysis. These 154 families in-
cluded 311 women with PALB2 mutations, of whom 
229 had breast cancer (Table 1), and 51 men with 
PALB2 mutations, of whom 7 had breast cancer. 
Among the 154 families, there were 48 different 
loss-of-function mutations in PALB2 (Fig. 1A, and 
Table S3 in the Supplementary Appendix).
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Risk of Cancer Calculated under Different 
Models
The risk of breast cancer for PALB2 mutation car-
riers was increased by a factor of 9.47 (95% CI, 
7.16 to 12.57), as compared with the breast-
cancer incidence in the general population of the 
United Kingdom between 1993 and 1997, under 
a single-gene model of constant relative risk 
across all ages (Table S4 in the Supplementary 
Appendix). The corresponding mean cumulative 
risk of breast cancer by 70 years of age was esti-
mated to be 47.5% (95% CI, 38.6 to 57.4). It ini-
tially appeared that the relative risk of breast 
cancer among PALB2 mutation carriers was 
higher at younger ages, with a relative risk of 
17.6 for mutation carriers 20 to 39 years of age, 
as compared with a relative risk of 8.7 for those 
40 to 79 years of age; however, models allowing 
for age-specific relative-risk parameters did not 
fit the data significantly better than the model 
with a constant relative risk (P = 0.07).
Models that accounted for residual familial ag-
gregation of breast cancer, in addition to the ag-
gregation attributable to PALB2 loss-of-function 
mutations, provided a better fit to the data (Ta-
ble S5 in the Supplementary Appendix). More-
over, a model including a background effect of 
familial factors on PALB2 mutation–associated risk 
provided a significantly better fit (P = 0.04) than 
did a model without modification of this risk (see 
the Supplementary Appendix). Such familial fac-
tors could include genetic, environmental, or life-
style variables that are correlated among relatives.
We fitted models in which parameters were 
expressed in terms of the risk for breast cancer 
in PALB2 mutation carriers relative to the base-
line incidence (i.e., for non–mutation carriers with 
no residual familial component) and were as-
sumed either to be constant with age or to vary 
with each decade of age (Table S5 in the Supple-
mentary Appendix). When this relative-risk pa-
rameter was constant, it was estimated to be 9.07 
(95% CI, 5.72 to 14.39). This model provided the 
best fit to the data. A model in which the risk 
relative to the baseline incidence was allowed to 
vary with age did not provide a significant im-
provement over the model with a constant rela-
tive risk (P = 0.40) (Table S5 in the Supplemen-
tary Appendix).
Age-specific estimates of risk among PALB2 
mutation carriers, over all background familial 
effects and risk ratios relative to population in-
cidences under the best-fitting model, are sum-
marized in Table 2. For PALB2 mutation carriers, 
the annual breast-cancer incidence increased 
with age, from 0.01% per year at 20 to 24 years 
of age to 1.60% per year at 50 to 54 years of age, 
then leveled off at approximately 1.4% per year 
thereafter. The relative risk associated with PALB2, 
averaged over all mutation carriers, was 8 to 9 up 
Table 1. Breast and Ovarian Cancer among Female PALB2 Mutation Carriers and Noncarriers and Untested Females, 
According to Age at Diagnosis or Data Censoring.
Age Group PALB2 Mutation Carriers Tested Noncarriers Untested
Unaffected
Breast 
Cancer
Ovarian 
Cancer* Unaffected
Breast 
Cancer
Ovarian 
Cancer* Unaffected
Breast 
Cancer
Ovarian 
Cancer*
number of women
<20 yr 1 0 0 1 0 0 172 0 0
20–29 yr 4 7 0 6 0 0 170 8 0
30–39 yr 2 50 0 24 5 0 218 32 1
40–49 yr 15 84 1 22 10 3 235 81 3
50–59 yr 23 55 4 30 10 3 321 62 8
60–69 yr 14 24 1 18 6 0 364 61 6
70–79 yr 12 7 2 11 1 0 315 34 7
≥80 yr 11 2 0 13 0 0 436 3 0
Total 82 229 8 125 32 6 2231 281 25
*  This category includes all diagnosed cases of ovarian cancer (including those diagnosed after a breast-cancer diagnosis).
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to 40 years of age, 6 to 8 between 40 and 60 
years of age, and approximately 5 at 60 years of 
age or older (Table 2, and Fig. S1 in the Supple-
mentary Appendix). The cumulative risk of breast 
cancer for female PALB2 mutation carriers was 
estimated to be 14% (95% CI, 9 to 20) by 50 years 
of age and 35% (95% CI, 26 to 46) by 70 years of 
age (Fig. 1B).
 Using the same approach, we estimated that 
the relative risk of ovarian cancer among PALB2
mutation carriers was 2.31 (95% CI, 0.77 to 6.97; 
P = 0.18). The relative risk of breast cancer for 
male PALB2 mutation carriers, as compared with 
the male breast-cancer incidence in the general 
population, was estimated to be 8.30 (95% CI, 
0.77 to 88.56; P = 0.08). The risk of breast cancer 
Figure 1. Loss-of-Function PALB2 Germline Mutations in Relation to Functional Domains and Structural Motifs 
of the PALB2 Protein, and Cumulative Breast-Cancer Risk for Female Mutation Carriers.
 Panel A is a schematic representation of the PALB2 gene together with all deleterious variants reported in this 
study, superimposed on the exonic structure of the gene, with functional domains and structural motifs indicated. 
The number of families with a certain allele is shown in parentheses after the mutation; no such number is given for 
mutations present only in single families. Numbers in square brackets after functional domains and structural mo-
tifs denote amino acid positions. Note that the KEAP1 interaction functional domain is an extended ETGE motif. 
Panel B shows the mean cumulative risk of breast cancer for female PALB2 mutation carriers and associated confi-
dence intervals.
Age (yr)
B Breast-Cancer Risk for Female PALB2 Mutation Carriers
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among female PALB2 mutation carriers was not 
significantly changed by including ovarian can-
cer or male breast cancer in the model.
Hormone-Receptor and HER2 Status
Breast-cancer estrogen-receptor status was avail-
able for 129 affected PALB2 mutation carriers, 
and the tumors in 95 of the 129 (74%) were es-
trogen-receptor–positive; this frequency is similar 
to that seen among patients with BRCA2 muta-
tions18 or with sporadic breast cancer. Addi-
tional information on progesterone-receptor and 
HER2 status was available for a total of 63 af-
fected PALB2 mutation carriers, 19 (30%) of whom 
had an estrogen-receptor–negative, progesterone-
receptor–negative, and HER2-negative (triple-neg-
ative) phenotype, as compared with a frequency of 
triple-negative status that ranges from 12 to 17% 
among unselected patients with breast cancer.19
Birth Cohort and Country of Residence
We evaluated whether birth cohort or country 
of residence affected breast-cancer risk among 
PALB2 mutation carriers. Carriers were divided 
into cohorts born before 1940, between 1940 and 
1959, and in 1960 or later (Table 3). The relative 
risk of breast cancer among PALB2 mutation car-
riers increased significantly as birth cohort be-
came more recent (P < 0.001). In contrast, we did 
not find evidence of differences in the relative-
risk estimates for PALB2 mutation carriers accord-
ing to country of residence (P = 0.11) (Table S6 in 
the Supplementary Appendix).
Familial Variance
In our analyses, we assumed that the total famil-
ial variance was approximately 1.66, on the basis 
of previous estimates from breast-cancer segre-
gation analyses.13,14 This is equivalent to a risk of 
breast cancer for first-degree relatives of patients 
with breast cancer that is approximately 2.3 times 
as high as that in the general population, in line 
with estimates from large epidemiologic studies.20 
When the total familial variance was assumed to 
be 1.2, equivalent to an approximate familial 
relative risk of 1.8 for first-degree relatives, the 
mean breast-cancer risk for female PALB2 muta-
tion carriers by 70 years of age was estimated to be 
36.9%. When the familial variance was assumed to 
be 2.0, equivalent to an approximate familial rela-
tive risk of 2.7, the corresponding mean breast-
cancer risk was estimated to be 34.3%. Therefore, 
the mean penetrance estimates were not sensitive 
to assumptions about the total familial variance, 
provided these were in line with observed pat-
terns of familial relative risks of breast cancer.
Age Group
Annual Mean 
Breast-Cancer 
Incidence†
Mean Relative Risk 
(95% CI)‡
%
20–24 yr 0.01 9.01 (5.70–14.16)
25–29 yr 0.07 8.97 (5.68–14.08)
30–34 yr 0.23 8.85 (5.63–13.78)
35–39 yr 0.50 8.54 (5.51–13.08)
40–44 yr 0.85 8.02 (5.29–11.95)
45–49 yr 1.27 7.31 (4.98–10.55)
50–54 yr 1.60 6.55 (4.60–9.18)
55–59 yr 1.45 5.92 (4.27–8.10)
60–64 yr 1.47 5.45 (4.00–7.33)
65–69 yr 1.19 5.10 (3.80–6.76)
70–74 yr 1.34 4.82 (3.63–6.33)
75–79 yr 1.34 4.56 (3.48–5.95)
*  The most parsimonious model allows for a constant risk 
ratio relative to the baseline breast-cancer incidence (ap-
plicable to those without a mutation and with no residual 
component) and equal residual and modifying variances.
†  Values are the estimated mean breast-cancer incidence 
over all background familial effects.
‡  Relative risks are for the comparison of the mean breast-
cancer incidence among PALB2 mutation carriers (over 
all background familial effects) with the age-specific 
breast-cancer incidence in the U.K. population from 1993 
to 1997.
Table 2. Estimated Age-Specific Relative Risk of Breast 
Cancer for Female PALB2 Mutation Carriers under the 
Most Parsimonious Model.*
Year of Birth Relative Risk (95% Floated CI)*
Before 1940 1.00 (0.59–1.69)
1940–1959 2.84 (1.64–4.93)
In 1960 or later 6.29 (2.81–14.10)
*  Floated CIs allow for comparisons of the relative-risk esti-
mates across all categories without the need to define a 
reference category. P < 0.001 for heterogeneity, from the 
comparison of the model allowing for a single relative-
risk parameter and the model with cohort-specific param-
eters.
Table 3. Estimated Relative Risk of Breast Cancer for 
Female PALB2 Mutation Carriers in Earlier and Later 
Birth Cohorts.
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Discussion
As clinical genetic testing for breast-cancer risk 
increasingly includes other genes in addition to 
BRCA1 and BRCA2, it is important to have robust 
risk estimates for women who carry loss-of-func-
tion mutations in genes such as PALB2. We esti-
mated the risk of breast cancer for PALB2 mutation 
carriers, using data from 154 families with 362 
members who had loss-of-function mutations in 
this gene. Under the best-fitting model, which in-
cluded a residual familial component, the mean 
risk of breast cancer for female PALB2 mutation 
carriers by 70 years of age was estimated to be 
35% (95% CI, 26 to 46). Models that allowed for 
a residual familial component influencing risk 
fit the data significantly better than did models 
without a modifying component, which suggests 
that breast-cancer risk for PALB2 mutation carriers 
is modified by other genetic or environmental 
factors that cluster in families, as shown previ-
ously for BRCA1 and BRCA2.10,21-23 Thus, the results 
suggest that no single set of penetrance esti-
mates applies to all PALB2 mutation carriers; the 
risk of breast cancer associated with PALB2 will 
also depend on genotypes at other modifying loci 
or on other familial factors.24 Until such modifiers 
of risk are identified, our model allows for 
PALB2-associated breast-cancer risk to be computed 
on the basis of both genotype and family history.
The cumulative risk estimates for female 
PALB2 mutation carriers, calculated with the use 
of different assumptions about family history of 
breast cancer, are shown in Table 4. By 70 years of 
age, breast-cancer risk ranged from 33% (95% CI, 
25 to 44) for a female carrier with no affected 
relatives to 58% (95% CI, 50 to 66) for a female 
carrier with two first-degree relatives who had 
breast cancer diagnosed by 50 years of age. Such 
differences in risk are consistent with previous 
observations,25 and it is possible that family his-
tory and PALB2 genotype should be considered 
together in determining the risk level and appro-
priate management.
On the basis of our mean risk estimates and 
an assumed PALB2 mutation carrier frequency of 
0.08% (see the Supplementary Appendix), PALB2 
loss-of-function mutations are estimated to ac-
count for approximately 2.4% of the familial ag-
gregation of breast cancer. However, this estimate 
is very imprecise, since it depends critically on the 
assumed PALB2 mutation frequency, for which 
data are currently scarce. Moreover, PALB2 muta-
tion frequency, and therefore the contribution of 
Age Cumulative Risk (95% CI)
Mean Estimate 
without Family 
History Taken 
into Account
Mother Unaffected at 50 Yr 
of Age, Maternal 
Grandmother Unaffected 
at 70 Yr of Age*
Mother with 
Breast Cancer at 
 35 Yr of Age*
Sister and 
Mother with 
Breast Cancer 
at 50 Yr of Age*
Mother and Maternal 
Grandmother with Breast 
Cancer at 50 Yr of Age*
percent
30 yr 0.4 (0.3–0.7) 0.3 (0.2–0.6) 0.8 (0.5–1.1) 0.9 (0.6–1.2) 0.7 (0.5–1.0)
35 yr 2 (1.0–2.4) 1 (0.9–2.2) 3 (2–4) 3 (2–4) 3 (2–4)
40 yr 4 (3–6) 3 (2–5) 7 (5–10) 8 (6–11) 7 (5–9)
45 yr 8 (5–12) 7 (5–11) 14 (9–20) 16 (12–21) 13 (10–18)
50 yr 14 (9–20) 13 (8–18) 23 (16–31) 27 (21–33) 22 (17–29)
55 yr 20 (14–28) 19 (13–26) 33 (24–43) 38 (30–45) 32 (25–40)
60 yr 26 (19–35) 24 (18–33) 40 (31–51) 46 (38–54) 40 (32–48)
65 yr 31 (23–42) 29 (22–39) 47 (37–58) 53 (45–61) 46 (38–55)
70 yr 35 (26–46) 33 (25–44) 52 (41–63) 58 (50–66) 51 (42–60)
75 yr 40 (30–51) 38 (28–48) 57 (46–68) 63 (55–71) 56 (47–65)
80 yr 44 (34–55) 41 (32–53) 61 (50–72) 67 (59–75) 61 (51–69)
*  Data are predicted breast-cancer risks obtained from the most parsimonious model, which allows for the residual fa-
milial aggregation effects in PALB2 mutation carriers and noncarriers.
Table 4. Risk of Breast Cancer for Female PALB2 Mutation Carriers, According to Family History of Breast Cancer.
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such mutations to familial aggregation, varies 
widely across populations.
In contrast, a consistent finding across popu-
lations is that breast-cancer risk among PALB2 
mutation carriers is significantly higher for wom-
en from more recent birth cohorts, a finding that 
has also been reported for carriers of loss-of-
function mutations in BRCA1 and BRCA2.26-28 
Even though we used calendar period–specific and 
cohort-specific incidences in our analyses, thus 
allowing for changes in breast-cancer incidence 
over time, this observation may be partly ac-
counted for by changes in surveillance methods, 
specifically for women with a strong family his-
tory of breast cancer. Although it appeared that 
there were differences in the PALB2-associated 
relative risks of breast cancer according to coun-
try, these differences were not significant in the 
present sample. Future large studies of PALB2 
mutation carriers, ideally including prospective 
cohorts, will be needed to further characterize 
cancer risks conferred by PALB2 mutations, to 
assess the role of factors such as lifestyle and 
hormone use on the breast-cancer risk of PALB2 
mutation carriers, and to investigate differences 
according to country of origin or specific PALB2 
mutations.
Our analysis included both families that were 
carefully selected through screening of families 
with multiple members who had breast cancer 
and families identified through population-based 
studies of patients with breast cancer. All our 
analyses were corrected for the methods of as-
certainment, in order to preclude bias in risk 
estimates caused by the inclusion of families 
with multiple cases. We recognize the variation 
and uncertainty in modes of ascertainment of 
families among different centers. Modeling like-
lihood as conditional on family history will reduce 
bias but can reduce the precision of estimates. It 
is expected that inclusion of data from more car-
rier families over time will improve precision.
The large number of families and confirmed 
PALB2 mutation carriers in our study offers ad-
ditional precision in estimating breast-cancer risk. 
Loss-of-function mutations in PALB2 confer a high-
er risk of breast cancer than do loss-of-function 
mutations in other genes for which there are 
good risk estimates, notably CHEK2 1100delC29 
and ATM.30-32 On the basis of our estimates, the 
breast-cancer risk for a PALB2 mutation carrier, 
even in the absence of a family history of breast 
cancer, would be classified as high according 
to various guidelines.33,34 This level of risk may 
justify adding PALB2 to genetic testing for BRCA1 
and BRCA2.
On the basis of our estimates of risk, women 
with loss-of-function mutations in PALB2 should 
be studied to determine whether enhanced sur-
veillance for breast cancer, in line with that of-
fered to women with mutations in BRCA2, can 
influence outcomes. Risk-reducing surgical op-
tions could also be tested. We found a nonsig-
nificant increase, by a factor of 2.3, in the risk 
of ovarian cancer for PALB2 carriers. The ques-
tion of whether loss-of-function mutations in PALB2 
confer a predisposition to ovarian cancer will re-
quire larger studies to address. We also estimated 
that the risk of breast cancer for male PALB2 
mutation carriers is increased by a factor of 8, 
which is consistent with previous reports,7,35,36 but 
the confidence interval for this estimate was very 
large. PALB2 loss-of-function mutations have been 
shown to confer a predisposition to pancreatic 
cancer,37,38 but the lifetime risk in carriers has 
yet to be quantified.
Our study includes most of the reported 
families with PALB2 mutation carriers, as well as 
many not previously reported, but it is still based 
on small numbers. Because of the widespread 
availability of multigene panels and whole-exome 
sequencing, screening for inherited loss-of-func-
tion mutations in PALB2 has begun to enter clini-
cal practice. As families with PALB2 mutations 
are identified, it will be valuable to collect fam-
ily history and other data for future analysis, in 
order to refine estimates of the cancer risks for 
PALB2 mutation carriers.
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